Illumina Inc. (NASDAQ:ILMN) received a $136.00 target price from investment analysts at Canaccord Genuity in a report issued on Friday. The firm currently has a a “hold” rating on the life sciences company’s stock. Canaccord Genuity’s target price suggests a potential downside of 26.43% from the company’s previous close.

Several other analysts also recently weighed in on ILMN. Zacks Investment Research upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Cantor Fitzgerald reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, June 29th. Mizuho lifted their price objective on shares of Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Vetr downgraded shares of Illumina from a “buy” rating to a “sell” rating and set a $142.96 price objective on the stock. in a research report on Tuesday, July 26th. Finally, Citigroup Inc. lifted their price objective on shares of Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $162.95.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) traded down 25.85% during mid-day trading on Friday, hitting $137.07. 5,461,422 shares of the stock traded hands. Illumina has a 12-month low of $127.10 and a 12-month high of $196.47. The firm has a market cap of $20.09 billion, a PE ratio of 46.94 and a beta of 0.47. The stock has a 50 day moving average price of $175.01 and a 200 day moving average price of $156.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. The firm had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted $0.80 EPS. On average, analysts expect that Illumina will post $3.53 earnings per share for the current fiscal year.

In other Illumina news, Director A Blaine Bowman sold 5,000 shares of Illumina stock in a transaction that occurred on Thursday, July 14th. The shares were sold at an average price of $147.14, for a total value of $735,700.00. Following the completion of the sale, the director now directly owns 20,704 shares in the company, valued at $3,046,386.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roy A. Whitfield sold 4,000 shares of Illumina stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $167.22, for a total transaction of $668,880.00. Following the completion of the sale, the director now owns 6,853 shares of the company’s stock, valued at $1,145,958.66. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in Illumina during the second quarter worth about $112,000. Ropes Wealth Advisors LLC boosted its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the period. Finally, Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.